Mesenchymal stem cells (MSCs) are able to infiltrate tumor tissues and thereby effectively deliver gene therapeutic payloads. Here, we engineered murine MSCs (mMSCs) to express a secreted form of the TNF-related apoptosis-inducing ligand (TRAIL), which is a potent inducer of apoptosis in tumor cells, and tested these MSCs, termed MSC.sTRAIL, in combination with conventional chemotherapeutic drug treatment in colon cancer models. When we pretreated human colorectal cancer HCT116 cells with low doses of 5-fluorouracil (5-FU) and added MSC.sTRAIL, we found significantly increased apoptosis as compared with single-agent treatment. Moreover, HCT116 xenografts, which were cotreated with 5-FU and systemically delivered MSC.sTRAIL, went into remission. Noteworthy, this effect was protein 53 (p53) independent and was mediated by TRAIL-receptor 2 (TRAIL-R2) upregulation, demonstrating the applicability of this approach in p53-defective tumors. Consequently, when we generated MSCs that secreted TRAIL-R2-specific variants of soluble TRAIL (sTRAIL), we found that such engineered MSCs, labeled MSC.sTRAIL DR5 , had enhanced antitumor activity in combination with 5-FU when compared with MSC.sTRAIL. In contrast, TRAIL-resistant pancreatic carcinoma PancTu1 cells responded better to MSC.sTRAIL DR4 when the antiapoptotic protein XIAP (X-linked inhibitor of apoptosis protein) was silenced concomitantly. Taken together, our results demonstrate that TRAIL-receptor selective variants can potentially enhance the therapeutic efficacy of MSC-delivered TRAIL as part of individualized and tumor-specific combination treatments.
The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a potent and specific inducer of apoptosis in tumor cells and can also act as a powerful cancer-preventive agent. 1, 2 It can bind to four membrane-bound receptors and one soluble receptor (TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4 and osteoprotegerin also known as DR4, DR5, decoy receptor 1 (DcR1), decoy receptor 2 (DcR2) and OPG, respectively). Both TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) contain a conserved cytoplasmic region termed the death domain (DD) that is required for TRAIL-induced apoptosis. 3 Upon binding of TRAIL, a protein complex is formed known as death-inducing signaling complex (DISC) consisting of TRAIL-R1 and/or TRAIL-R2, the adaptor protein Fas-associated death domain (FADD) and procaspase-8. 4 Activation of caspase-8 at the DISC and subsequent activation of effector caspases leads to apoptosis. 5 In contrast, TRAIL receptors 3 and 4 (TRAIL-R3 and TRAIL-R4) and the soluble receptor OPG have inhibitory functions, because they lack the intracellular DDs, and are therefore regarded as decoy receptors. 1 Therefore, one potential way of improving the therapeutic efficacy of TRAIL is to generate agents that act in a TRAIL-R-specific way, preferring one of the two death receptors and potentially avoiding the decoy receptors. To this end, agonistic antibodies directed against one of the two apoptosis-inducing TRAIL-Rs have been developed and tested in various experimental systems as well as in the clinic. [6] [7] [8] [9] In addition, engineered variants of the TRAIL protein, containing specific amino-acid changes leading to specific targeting of TRAIL-R1 or TRAIL-R2 have beenin vitro and in vivo. [10] [11] [12] [13] However, in clinical trials with recombinant TRAIL (rTRAIL) protein and agonistic antibodies to TRAIL-R2, only moderate therapeutic activities have been found. 14 A possible explanation for the problems with recombinant protein and antibodies is limited bioavailability owing to short half-life of the protein or restricted accessibility of large antibodies to tumor tissue, respectively. 15 Cell and gene therapy approaches provide a potential strategy to overcome such limitations and several cellular gene delivery vectors utilizing TRAIL as its therapeutic payload have shown efficacy in experimental tumor models. [16] [17] [18] [19] [20] In particular, mesenchymal stem cells (MSCs) have been used in this context, as they are known to readily infiltrate tumor tissues. 21, 22 However, limitations to this approach have been highlighted in a recent study that demonstrated the requirement for substantial intratumoral presence of MSCs to afford growth inhibition in a colorectal carcinoma model. 23 Therefore, it is essential to derive as much therapeutic effect from the tumor-infiltrating MSCs as possible, because in a clinical setting the number of MSCs that can be safely injected and consequently the number of tumor-infiltrating MSCs might be limited. Thus, the use of sTRAIL as compared with full-length membrane-bound TRAIL 19 and integration of TRAIL-Rspecific variants [10] [11] [12] [13] are valuable approaches to augment the antineoplastic effects of the MSC-based delivery system. A further barrier for TRAIL therapies is that a substantial proportion of tumors are relatively resistant to the effects of TRAIL. 24 To this end, we could show that a sensitization approach with the commonly used anticancer compound 5-fluorouracil (5-FU) in conjunction with systemically administered MSC.sTRAIL worked in vitro and in vivo. The effect was mediated by protein 53 (p53)-independent increases in the expression of TRAIL-R2, and consequently MSCs secreting a TRAIL-R2-specific sTRAIL variant (MSC.sTRAIL DR5 ) gave rise to significantly higher apoptosis than MSC.sTRAIL (wildtype sTRAIL) or MSC.sTRAIL DR4 (TRAIL-R1-specific variant) in 5-FU-pretreated HCT116 cells. In a second sensitization approach, we targeted the antiapoptotic protein XIAP (Xlinked inhibitor of apoptosis protein) by RNA interference (RNAi) in TRAIL-resistant pancreatic carcinoma cells and could show that MSC.sTRAIL DR4 exerted significantly increased apoptosis-inducing activity as compared with MSC.sTRAIL or MSC.sTRAIL DR5 . Hence, MSC-mediated delivery of optimized sTRAIL variants to tumors combined with conventional chemotherapy or inhibition of apoptosis resistance factors such as XIAP could become a novel, patient-tailored treatment strategy for various oncological diseases.
Results
Combined treatment of 5-FU and TRAIL leads to synergistic apoptosis induction. Because TRAIL as a stand-alone strategy is unlikely to be efficacious in all cancer types and cases owing to apoptosis resistance of tumor cells, we set out to test optimized TRAIL-based approaches utilizing combination treatments with the cytotoxic drug 5-FU and MSC-mediated delivery of sTRAIL. First, we determined the minimal concentrations of rTRAIL and 5-FU that could be used in a combination treatment of colorectal cancer cells. HCT116 cells were treated with 5-FU at concentrations of 10, 50, 100, 200 and 400 mM ( Figure 1a ) and rTRAIL at concentrations of 0.25, 0.5, 1, 2 and 5 ng/ml ( Figure 1a) . The results show increasing apoptosis levels with rising concentrations of the respective apoptosisinducing agent. For our combination treatment experiment, we chose concentrations of the two agents that gave rise to relatively low specific apoptosis levels and thus pretreated HCT116 cells with 10 mM 5-FU for 24 h followed by 1 ng/ml rTRAIL for an additional 24 h before we measured cell death. This combined treatment resulted in 37±0.6% apoptosis as compared with 2.6 ± 0.4% and 10.5 ± 0.4% apoptosis, respectively, for the single treatments (Figure 1a ). Apoptosis could be completely blocked by the pan-caspase inhibitor zVAD (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone), demonstrating that the detected cell death was a caspase-dependent apoptotic process ( Figure 1a) .
A significant problem for clinical use of TRAIL is effective delivery and sufficient bioavailability in tumor lesions of the recombinant protein or agonistic TRAIL-R antibodies. 15 In order to overcome this problem, we and others have exploited the tumor-infiltrating properties of MSCs to deliver sTRAIL. [17] [18] [19] Here, we have constructed an adenoviral (Ad) vector (Ad.sTRAIL) that contained the ectodomain of TRAIL (aa114-aa289) fused to the secretory signal peptide from the human Fibrillin-1 gene (hFIB), a Furin cleavage site (Furin CS) and an Isoleucine zipper (ILZ) domain under the control of the cytomegalovirus (CMV) promoter/enhancer element (Figure 1b) . 25 The vector Ad.sTRAIL was used to transduce MSCs, which had been characterized by their capacity for adipogenic, osteogenic and chondrogenic differentiation (Figure 1b) as well as by fluorescence-activated cell sorting (FACS) analyses with an array of surface marker antibodies. The results show that our murine MSCs (mMSCs) are CD29 þ , Sca-1 þ , CD44 þ , CD11b À , CD19 À , CD117 À , CD45 À and Ter À 119 À , demonstrating their purity and ruling out a contamination with fibroblasts and hematopoietic cells (Figure 1b) . The resulting modified MSCs that expressed and secreted sTRAIL were termed MSC.sTRAIL (Supplementary Figure S1a-d) . Mixing of MSC.sTRAIL with HCT116 cells that had been pretreated with 10 mM 5-FU for 24 h gave rise to significant increased apoptosis levels in the double-treated cells (5-FU/MSC.sTRAIL) as compared with the single treatments or a 5-FU/MSC.DsRed control combination ( Figure 1c ). As we obtained the same significant sensitization effect when we transferred the medium supernatant from MSC.sTRAIL 48 h after transduction with Ad. sTRAIL onto 5-FU-pretreated HCT116, we could conclude that the effect was indeed exerted by secreted sTRAIL and not via direct MSC-cancer cell interactions (Figure 1c ).
Combined treatment of 5-FU and TRAIL is efficacious and safe in vivo. Based on our in vitro findings we examined the utility of 5-FU in combination with MSC.sTRAIL in HCT116 xenografts. First, we tested the duration of transgene expression in adenovirally transduced MSCs in vitro to inform our in vivo regimen (Supplementary Figure  S2) and assessed the effect of 5-FU on MSCs and their potential to secrete sTRAIL as well as to induce apoptosis in Cells were treated for 48 h with the respective doses of 5-FU (left). HCT116 cells were treated with rTRAIL with increasing concentrations and apoptosis measured 24 h later (center). Apoptosis measurements after treatment with 10 mM 5-FU for 48 h, treatment with rTRAIL at 1 ng/ml for 24 h or pretreatment with 10 mM 5-FU for 24 h followed by 1 ng/ml rTRAIL for an additional 24 h. Addition of zVAD directly to the HCT116 cells before 5-FU pretreatment completely inhibited apoptosis of the combined treatment (5-FU followed by rTRAIL). Carrier (dimethylsulfoxide (DMSO)) treatment had no effect (right). Data represent averages ± S.E.M. (Figure 2b ). In contrast, 5-FU/MSC.sTRAIL clearly showed a lot of cellular debris mixed with collagen fibers replacing the proliferating cells that were present in the other samples ( Figure 2b ). In addition, nuclear proliferating cell nuclear antigen (PCNA) protein expression, which is observed during DNA synthesis and generally represents cellular proliferating activity, was detected immunohistochemically (Figure 2b ). In the MSC.DsRed and 5-FU/MSC.DsRed groups, PCNA levels were higher compared with MSC.sTRAIL tumor samples and were almost absent in sections from the 5-FU/MSC.sTRAIL group (Figure 2b ). Hence, whereas 5-FU and MSC.sTRAIL as single-agent regimens possess significant but limited anticancer activities, the combination of both gave rise to tumor remission.
Next, we tested the safety of combined 5-FU/TRAIL treatments on primary murine and human cells. To this end, we incubated murine and human MSCs with 10 mM 5-FU for 24 h followed by rTRAIL (10 ng/ml) for an additional 24 h period. When we measured apoptosis in these cells, we found that they were resistant to the single treatments as well as to the combination of 5-FU and rTRAIL ( Figure 2c ). Furthermore, we examined the livers of mice that had received 5-FU injections followed by MSC.sTRAIL and could not detect any signs of tissue injury or cell death in these tissue samples (Figure 2d ), indicating that the present novel therapeutic approach is safe.
The molecular mechanism of TRAIL sensitization by 5-FU. In order to further improve TRAIL-based combination treatments, a better understanding of the underlying molecular mechanism(s) of the observed sensitization is important. First, we analyzed caspase-8 activation, which is one of the initial molecular events in the TRAIL-triggered apoptosis pathway, in 5-FU/TRAIL-treated HCT116 cells. Our results demonstrate that caspase-8 activation is markedly increased in cells exposed to the combined treatment as compared with cells treated with either 5-FU or rTRAIL alone (Figure 3a) . In order to show that the 5-FU sensitization effect is indeed transduced through the canonical caspase-8-initiated demonstrating that caspase-8 was the sole initiator caspase and that the sensitization effect of 5-FU was not mediated by mechanisms outside of the normal extrinsic apoptosis pathway (Figure 3a) . Thus, molecularly, the observed 5-FUmediated sensitization is located at the level of caspase-8 activation or upstream of it. Although these results show that caspase-8 is required for 5-FU/TRAIL-triggered apoptosis, we could not detect any indications that 5-FU gave rise to elevated levels of caspase-8, thereby making a role as molecular driver of the observed 5-FU sensitization effect unlikely. Instead, we turned to the antiapoptotic protein cFlip (cellular FLICE-like inhibitory protein), as others have implicated 5-FU-triggered downregulation of cFlip in the sensitization effect. 26 However, although decreased levels of cFlip protein after 5-FU stimulation could indeed explain enhanced caspase-8 activation, we were unable to detect any decreases in cFlip levels ( Figure 3b) . Next, we examined changes in the surface levels of TRAIL-R1 and TRAIL-R2 by FACS after 5-FU treatment, because increased TRAIL-R expression could lead to higher caspase-8 activation and apoptosis in response to TRAIL, and as in particular TRAIL-R2 has been shown to be upregulated by 5-FU via a mechanism that is believed to be p53 dependent. 27 Following 5-FU treatment, we detected a substantial rise in TRAIL-R2 expression but almost no effect on the TRAIL-R1 levels (Figure 3b ). To test whether the increased TRAIL-R2 levels could prime the cells for increased TRAIL responsiveness, we generated stable TRAIL-R2 and as controls TRAIL-R1 knockdown clones in HCT116 cells, labeled HCT.shDR5 and HCT.shDR4, respectively (Figure 3c ). When the HCT.shDR4 cells were treated with 5-FU followed by rTRAIL, we observed significantly elevated levels of cell death as compared with control cells (Figure 3c ). In contrast, in HCT.shDR5 cells, 5-FU/TRAIL-induced apoptosis was significantly reduced (Figure 3c ). These results strongly point to the upregulation of TRAIL-R2 as the molecular driver of the 5-FU-induced sensitization effect. In contrast, TRAIL-R1 not only had no role in the observed sensitization, but silencing of this receptor gave rise to a significant increase in 5-FU/ TRAIL-induced apoptosis, most likely owing to the fact that TRAIL-R2 molecules can form more readily active homotrimers and consequently induce a higher level of apoptosis with no or very little interfering TRAIL-R1 present in the membrane. Following these findings, we wondered whether the upregulation of TRAIL-R2 and consequent sensitization to TRAIL is p53 dependent. When we subjected HCT116 and HCTp53 À / À cells to the standard 5-FU pretreatment and measured TRAIL-R2 and TRAIL-R1 levels, we found TRAIL-R2 protein expression to be upregulated in HCTp53 À / À cells 24 h later as compared with HCT116 cells (Figure 3d ), whereas TRAIL-R1 levels were almost unchanged in both cell types. Consequently, 5-FU-mediated TRAIL-induced apoptosis sensitization reached the same levels in HCTp53 À / À cells as in HCT116 cells, although in a timedelayed fashion (Figure 3d ). To test that 5-FU sensitization is not restricted to HCT116 and HCTp53 À / À cells, we additionally analyzed HT-29 human colorectal cancer cells, which harbor a R273H p53 mutation, and found that they could also be sensitized to the apoptosis-inducing effects of TRAIL by pretreatment with 5-FU (Figure 3d ). These results demonstrate that the 5-FU-mediated sensitization strategy is independent of p53, but based on p53 status, modified regimens have to be used with respect to the optimal time point of the TRAIL or MSC.sTRAIL administration. Furthermore, given the importance of TRAIL-R2, we hypothesized that the use of TRAIL-R-specific variants that specifically induce apoptosis via TRAIL-R2 might increase the efficacy of the MSC.sTRAIL system further.
Soluble TRAIL variants sTRAIL DR5 and sTRAIL DR4 are specific for TRAIL-R2 and TRAIL-R1, respectively. In addition to the wild-type TRAIL construct containing the consensus TRAIL cDNA sequence, we integrated two TRAIL-R-specific variants, one selective for TRAIL-R1 (DR4) and one for TRAIL-R2 (DR5) into our expression construct. These variants were designed by using the automatic design algorithm FOLD-X 28 and have been previously described and tested as recombinant proteins (without the ILZ). 13 One amino-acid sequence change was introduced into the TRAIL segment, namely an aspartate to histidine change at position 269 (D269H) to generate the DR5-specific variant (sTRAIL DR5 ), whereas the DR4-specific variant (sTRAIL DR4 ) was generated by a serine to argenine change at position 159 (S159R) (Figure 4a ). The resulting expression constructs were transfected into 293 cells, tested by Western blot (Figure 4b ) and the level of sTRAIL in the supernatant measured by ELISA (Figure 4b ). The results demonstrate that the different sTRAIL variants were expressed and secreted at comparable levels. In order to confirm the TRAIL receptor specificity of the sTRAIL DR5 and sTRAIL DR4 variants, we used the HCT.shDR5 and HCT.shDR4 cells. When these cells were treated with supernatants from 293 cells secreting sTRAIL DR5 or sTRAIL DR4 , we found that HCT.shDR5 cells showed markedly reduced apoptosis in response to sTRAIL DR5 in comparison with HCT116 cells, whereas the cell death levels with sTRAIL DR4 and sTRAIL were normal (Figure 4c ). In contrast, HCT.shDR4 exhibited significantly decreased apoptosis with sTRAIL DR4 , but elevated levels with sTRAIL DR5 (Figure 4c ). These findings indicate that the sTRAIL variants indeed induce apoptosis via one of the two receptors in a specific manner and that they hold promise to improve the effectiveness of our MSC.sTRAIL system.
The variants sTRAIL DR5 and sTRAIL DR4 induce increased apoptosis in different cancer cells. To further test the activities of the TRAIL-R-specific variants, we transfected 293 cells with the three constructs expressing sTRAIL, sTRAIL DR5 and sTRAIL DR4 , respectively, harvested the supernatant media after 48 h, adjusted the sTRAIL concentration to 2 ng/ml sTRAIL and transferred the supernatants onto an array of cancer cells. We found cancer cell-specific differences with regard to their propensity to undergo apoptosis via TRAIL-R2 or TRAIL-R1. On one hand, human ovarian cancer A2780 cells, human pancreatic BxPC-3 cells, human colorectal cancer cells HCT116 and Colo205 cells showed increased apoptosis when treated with supernatants from sTRAIL DR5 -producing 293 cells (Figure 5a) , and on the other hand, human pancreatic carcinoma Colo357 cells and human cervical cancer Hela cells exhibited elevated cell sTRAIL variants and 5-FU lead to tumor remission R Yu et al death rates with sTRAIL DR4 (Figure 5b ). The differences in specific apoptosis between the sTRAIL DR5 and sTRAIL DR4 , they did not fully reveal the advantages of the respective TRAIL variants over wild-type sTRAIL. We hypothesized that decreasing sTRAIL concentrations would better unearth such differences. Therefore, we treated Colo205 cells with a lower dose of sTRAIL and its variants (0.5 ng/ml). We found that at this concentration sTRAIL DR5 induced apoptosis levels that were equal to those obtained with 2 ng/ml, that is, 495%, whereas apoptosis induction with sTRAIL and sTRAIL DR4 dropped to levels measured with control supernatants (Figure 5c ). These results demonstrate that sTRAIL variants can have a markedly augmented therapeutic potential as compared with wild-type sTRAIL. Thus, we sought to combine TRAIL-R-specific variants with the MSC-based delivery system. DR5 , respectively. The levels of sTRAIL were visualized by western blot and found to be equal for all three sTRAIL forms (Figure 6a ). Mixing MSC.sTRAIL DR5 with Colo205 cells at cellular ratios of 1 : 5, 1 : 10 and 1 : 20 led to significantly more apoptosis than with MSC.sTRAIL or MSC.sTRAIL DR4 , demonstrating the higher susceptibility of Colo205 cells to undergo apoptosis via a TRAIL-R2-mediated pathway (Figure 6b ). When we assayed Figure 4 Receptor-specific sTRAIL variants are expressed and act specifically. (a) Schematic drawing of the sTRAIL, sTRAIL DR5 (TRAIL-R2-specific) and sTRAIL
DR4
(TRAIL-R1-specific) constructs. The TRAILR-specific variants were generated by site-directed mutagenesis inserting a D269H and an S159R amino-acid exchange in the sTRAIL ectodomain, respectively. The expression was driven by a conventional CMV promoter/enhancer element in all three constructs. (green) or sTRAIL DR4 (red) were normalized to 2 ng/ml TRAIL (the EGFP control was diluted 1 : 2 in fresh medium) and then applied to HCT116, HCT.shDR5 and HCT.shDR4 cells, respectively, before apoptosis was measured 24 h later. Data represent averages ± S.E.M. (n ¼ 3, P ¼ 0.008, P ¼ 0.01, P ¼ 0.004) sTRAIL variants and 5-FU lead to tumor remission R Yu et al apoptosis at the molecular level, we found that MSC.sTRAIL DR5 more profoundly induced caspase-8 activation than MSC.sTRAIL and MSC.sTRAIL DR4 (Figure 6b ). These results were supported by caspase-3 western blots that showed full caspase-3 activation in MSC.sTRAIL DR5 -treated Colo205 cells, significantly less in MSC.sTRAILstimulated cells and no caspase-3 activation in the MSC.sTRAIL DR4 sample (Figure 6b ). In contrast, in Hela cells, addition of MSC.sTRAIL DR4 gave rise to markedly higher apoptosis levels compared with MSC.sTRAIL and MSC.sTRAIL DR5 (Figure 6c ). Analyzing caspase-8 activation by western blot revealed that in accordance with the apoptosis results, MSC.sTRAIL DR4 gave rise to the strongest caspase-8 activation (Figure 6c ). In addition, caspase-3 immunoblots showed that only MSC.sTRAIL DR4 caused full activation as evident by the appearance of the active fragments (Figure 6c ). Taken together, these results show that MSCs can be utilized to secrete sTRAIL variants that in turn can more effectively induce apoptosis in different cancer cells. Combination treatments enhance the effects of MSC. sTRAIL DR5 and MSC.sTRAIL DR4 in colon and pancreatic cancer cells. After having demonstrated the utility of 5-FU sensitization to MSC.sTRAIL-induced apoptosis in vivo on one side as well as the potential of TRAIL-R-specific variants on the other, we sought to combine these two approaches. In particular, as we had found that 5-FU sensitization to TRAIL was mediated by TRAIL-R2 and its upregulation, we hypothesized that TRAIL-R2-specific variants could afford superior cancer cell killing effects in this context. We pretreated HCT116 cells with 5-FU for 24 h, after which MSC.sTRAIL, MSC.sTRAIL DR5 and MSC.sTRAIL DR4 were added for another 24 h, before apoptosis was measured. We found that pretreatment with 5-FU led to significantly increased apoptosis levels after treatment with MSC.sTRAIL DR5 compared with MSC.sTRAIL and MSC. sTRAIL DR4 (Figure 7a ). To study the specificity of MSC.sTRAIL DR4 and MSC.sTRAIL DR5 in combination with 5-FU, we mixed them with HCT116, HCT.shDR4 and HCT.shDR5 cells that had been pretreated with 5-FU. Our DR5 showed higher apoptosis levels whereas in HCT.shDR5 the 5-FU sensitization effect was blocked, demonstrating that it was mediated by TRAIL-R2 (Figure 7a) . Noteworthy, MSC.sTRAIL DR4 exerted augmented apoptosis-inducing activity on HCT.shDR5, as no TRAIL-R2 could impede the formation of TRAIL-R1 homotrimers, resulting in more efficient apoptosis induction by the TRAIL-R1-specific variant (Figure 7a) . Accordingly, MSC.sTRAIL DR5 gave rise to more cell death in 5-FUpretreated HCT.shDR4 cells (Figure 7a) . Thus, MSC.sTRAIL DR5 is the preferred system in combination with 5-FU in this case. However, in addition to Hela and Colo357 cells (Figure 5b ), we and others have shown that in pancreatic cancer cells TRAIL-induced apoptosis is preferentially mediated via TRAIL-R1 and is profoundly enhanced by XIAP inhibition. 29, 30 Therefore, to also test utility of TRAIL-R1-specific variants in conjunction with an alternative sensitization approach to 5-FU, namely XIAP inhibition, we generated stable XIAP knockdown clones of the TRAILresistant pancreatic PancTu1 cancer cell line. These clones were named PancTu1.shXIAP and were shown to harbor no detectable XIAP levels by western blot (Figure 7b) (Figure 7b ). These findings are in line with our previous findings 29, 30 and underline that pancreatic cancer cells undergo apoptosis preferentially via TRAIL-R1. In summary, TRAIL-R-specific variants offer a substantial improvement over normal TRAIL as they can better target TRAIL-resistant cancer cells and act more specifically and effectively in combined treatment approaches.
Discussion
MSCs are pluripotent adult stem cells that are normally derived from bone marrow and have the potential to differentiate in vitro along numerous mesenchymal lineages. 31 As MSCs have been shown to infiltrate tumor tissues, 21, 22 they have been employed in various experimental cancer therapeutic approaches, including those that make use of their proposed intrinsic anticancer properties or as a delivery vehicle for therapeutic anticancer transgenes. 32 To this end, we and others have shown that MSCs expressing TRAIL led to growth retardation or remission of human lung, glioblastoma, breast and pancreatic carcinoma xenografts, respectively, as well as inhibition of metastasis formation. 17, 19, [33] [34] [35] In order to increase the effects of MSCmediated TRAIL delivery further, we analyzed pretreatment of cancer cells with 5-FU in combination with MSC.sTRAIL. 5-FU is a pyrimidine analog that is used in the treatment of cancer. 36 It belongs to the family of drugs called antimetabolites and works through irreversible inhibition of thymidylate synthase. 5-FU has been shown to sensitize to TRAIL-induced apoptosis via various mechanisms including upregulation of TRAIL-R expression and/or downregulation of the anti-apoptotic protein cFlip. 26 As its principal use is in colorectal cancer, in which it has been the established form of chemotherapy for decades, we tested 5-FU pretreatment followed by MSC.sTRAIL in HCT116 human colorectal cancer cells. We found pretreating with low doses of 5-FU greatly enhanced apoptosis when the HCT116 cells were subsequently mixed with MSC.sTRAIL. Furthermore, when we established HCT116 xenografts in mice, pretreated them with 5-FU followed by systemic administration of MSC.sTRAIL, we saw complete remission of the tumors as compared with partial responses in the cohort treated with MSC.sTRAIL alone. HCT116 cells are p53 proficient, whereas a substantial fraction of tumors are p53 mutated and/or dysfunctional. Therefore, in order to assess whether this sensitization strategy would also be applicable in p53-defective tumor cells, we analyzed p53-mutated and p53-negative colon cancer cells, HT-29 and HCTp53 À / À cells, respectively. We were able to sensitize both cell lines to the effects of TRAIL by 5-FU pretreatment, demonstrating that the approach also has utility in p53-deficient tumors. Subsequently, we sought to elucidate the underlying molecular mechanism of the 5-FU sensitization in order to be able to design further improvements into the MSC.sTRAIL system. We found that this sensitization effect was caused by 5-FUinduced, p53-independent upregulation of TRAIL-R2, as RNAi-mediated silencing of TRAIL-R2, but not of TRAIL-R1, resulted in inhibition of 5-FU/TRAIL-induced apoptosis. Hence, we set out to develop MSCs that express and secrete TRAIL variants that specifically target TRAIL-R2 to achieve greater apoptosis induction in 5-FU-treated tumor cells. First, we cloned the cDNAs coding for TRAIL variants that acted through TRAIL-R1, as control, and TRAIL-R2, respectively, into adenoviral expression constructs, which were used to transduce MSCs, giving rise to MSC.sTRAIL DR4 and MSC.sTRAIL DR5 . Indeed, when we mixed 5-FU-stimulated HCT116 cells with MSC.sTRAIL, MSC.sTRAIL DR4 or MSC.sTRAIL DR5 , we measured the highest apoptosis levels in the cancer cells that were treated with MSC.sTRAIL DR5 . Taken together, a targeted therapy with MSC.sTRAIL DR5 in combination with 5-FU appears to be a viable treatment approach even for p53-deficient tumors.
However, many tumors are resistant to TRAIL-induced apoptosis owing to mechanisms downstream of the receptor and the DISC, which means that 5-FU-mediated TRAIL-R upregulation (alone) would not be a viable sensitization strategy. To this end, we and others have documented the importance of the antiapoptotic protein XIAP, known to be frequently upregulated in cancers, and its utility as a therapeutic target. 37, 38 Pancreatic cancers in particular are known to be aggressive and resistant to apoptosis at least in part owing to high XIAP levels. 39 In the present study, we generated stable XIAP knockdown clones by RNAi in the pancreatic cancer cell line PancTu1 and treated them with our array of MSC.sTRAIL variants. We found that in contrast to their parental counterparts, XIAP-silenced cells were sensitive to the effects of MSC-produced sTRAIL, 19 and also found that in this context PancTu1 responded better to TRAIL-R1-specific sTRAIL, as we have reported previously in a similar approach using agonistic TRAIL-R1-specific antibodies. 30 As several XIAP/IAP inhibitors are currently in clinical tests, the silencing of XIAP or its functions is a potential approach and can be achieved either pharmacologically or through improved RNAi tools [40] [41] [42] in a potential, future clinical setting. Furthermore, although MSC.sTRAIL DR5 were the optimal system in particular for 5-FU-primed colorectal cancer cells, the effects on other tumor cells that were not treated with 5-FU were more divergent. In Colo205, HCT116, BxPc-3 and A2780 cells, sTRAIL DR5 showed the best effects, whereas sTRAIL DR4 induced more apoptosis in Hela, Colo357 and PancTu1.shXIAP cells, indicating that in certain cases TRAIL-R1-specific variants are more efficacious. Therefore, it would be valuable to be able to predict the responsiveness of cancer cells to the different TRAIL variants. To this end, we have previously reported that the expression levels of the different TRAIL-Rs can be a predicting factor for TRAIL responsiveness. 43 In line with those results, on Colo205 cells, which trigger apoptosis preferentially via TRAIL-R2, TRAIL-R1 is undetectable. Thus, although the predictive potential of TRAIL-R expression is limited, it can still serve as a first-line test aiding in deciding which TRAIL variant to use. Overall, our results demonstrate that TRAIL-R-specific TRAIL variants are significantly more efficacious than wild-type TRAIL, in particular in combination with 5-FU.
Materials and Methods
Reagents and cell culture. All chemicals and reagents unless otherwise stated, were purchased from Sigma (St Louis, MO, USA). Media were purchased from Invitrogen (Carlsbad, CA, USA) unless otherwise stated. Recombinant TRAIL was from R&D Systems (Minneapolis, MN, USA) and zVAD from Santa Cruz (Santa Cruz, CA, USA). Antibodies and cells are described in the Supplementary Materials and Methods section. 293 cells were transiently transfected using the calcium phosphate transfection method, which is described in more detail in the Supplementary Materials and Methods section.
Apoptosis assay. Apoptosis was measured according to Nicoletti et al. 44 and has been described previously. 45 Please see Supplementary Materials and Methods for detail.
Generation of adenoviral vectors and transduction of MSCs.
Recombinant E1/E3-deleted adenoviral vectors (Ad.sTRAIL, Ad.sTRAIL DR4 , Ad.sTRAIL DR5 and control Ad.DsRed) were generated using the ViraPower adenoviral expression system (Invitrogen) as described earlier. 34 Transduction of MSCs was carried out as described earlier. 34 TRAIL variants, sTRAIL DR5 (D269H) and sTRAIL DR4 (S159R), were generated using the Quick-Change site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) and confirmed by DNA sequencing. Please see Supplementary Materials and Methods for detail.
Isolation, expansion and differentiation assays of MSCs. MSCs from 4-to 6-week old FVB/N (FVB/n mouse strain) mice were prepared based on the method of Peister et al. 46 The cells were grown in Dulbecco's modified Eagle's medium (DMEM)-low glucose with 100 U/ml penicillin, 100 mg/ml streptomycin and 15% fetal bovine serum (FBS). Differentiation assays for MSCs were carried out as described previously. 21 The murine MSCs (mMSCs) are generally referred to as MSCs throughout the text.
Cell surface staining and FACS analyses. The surface expression of TRAIL-Rs was measured by incubating cells with R-phycoerythrin (PE)-conjugated mouse anti-human TRAIL-R1 and mouse anti-human TRAIL-R2 as described previously. 34 The same procedure was used to stain for CD11b, CD19, CD117, CD45, TER-119, CD29, Sca-1 and CD44.
